Effects of parenteral nutrition without and with growth hormone on growth hormone/insulin-like growth factor-1 axis after hepatectomy in hepatocellular carcinoma with liver cirrhosis

Journal of Parenteral and Enteral Nutrition

Volumn 31, Issue 6, 2007, Pages 496-501

  Cao, Jie ^a   Luo, Shi Min ^a   Liang, Lijian ^b   Lai, Jiaming ^b  

^a GUANGZHOU FIRST PEOPLE'S HOSPITAL   (China)

^b SUN YAT SEN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; DNA; GROWTH HORMONE; HUMAN GROWTH HORMONE; KI 67 ANTIGEN; MESSENGER RNA; PARENTERAL SOLUTION; PREALBUMIN; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C;

ADULT; ARTICLE; CHOLELITHIASIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HORMONAL THERAPY; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOMODULATION; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FUNCTION; LIVER HEMANGIOMA; MAJOR SURGERY; MALE; PARENTERAL NUTRITION; PRIORITY JOURNAL; PROTEIN DEGRADATION; RANDOMIZED CONTROLLED TRIAL; RECURRENCE RISK; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SURVIVAL RATE; SURVIVAL TIME;

CARCINOMA, HEPATOCELLULAR; DISEASE-FREE SURVIVAL; FEMALE; GROWTH HORMONE; HEPATECTOMY; HUMANS; IMMUNOHISTOCHEMISTRY; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 3; INSULIN-LIKE GROWTH FACTOR I; KI-67 ANTIGEN; LIVER CIRRHOSIS; LIVER NEOPLASMS; MALE; MIDDLE AGED; PARENTERAL NUTRITION; POSTOPERATIVE PERIOD; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TREATMENT OUTCOME;

EID: 35748944107     PISSN: 01486071     EISSN: None     Source Type: Journal    
DOI: 10.1177/0148607107031006496     Document Type: Article

References (29)

1. Baruch Y. The liver: a large endocrine gland. J Hepatol. 2000;32:505-507.
2. Furstenberger G, Senn HJ. Insulin-like growth factors and cancer. Lancet Oncol. 2002;3:298-302.
3. Mattera D, Capuano G, Colao A, et al. Increased IGF-I: IGFBP-3 ratio in patients with hepatocellular carcinoma. Clin Endocrinol (Oxf). 2003;59:699-706.
4. Caregaro L, Alberino F, Amodio P, et al. Nutritional and prognostic significance of insulin-like growth factor 1 in patients with liver cirrhosis. Nutrition. 1997;13:185-190.
5. Inaba T, Saito H, Inoue T, et al. Growth hormone/insulin-like growth factor 1 axis alterations contribute to disturbed protein metabolism in cirrhosis patients after hepatectomy. J Hepatol. 1999;31:271-276.
6. Kaaks R. Nutrition, insulin, IGF-1 metabolism and cancer risk: a summary of epidemiological evidence. Novartis Found Symp. 2004;262:247-260.
7. Liang LJ, Luo SM, Hu WJ. Effects of amino acid solution and recombinant human growth hormone on growth hormone/insulin like growth factor-1 axis in rats with liver cirrhosis. Zhonghua Wai Ke Za Zhi. 2005;43:697-701.
8. Schoenle EJ, Zapf J, Prader A, Torresani T, Werder EA, Zachmann M. Replacement of growth hormone (GH) in normally growing GH-deficient patients operated for craniopharyngioma. J Clin Endocrinol Metab. 1995;80:374-378.
9. Vyzantiadis T, Theodoridou S, Giouleme O, Harsoulis P, Evgenidis N, Vyzantiadis A. Serum concentrations of insulin-like growth factor-I (IGF-I) in patients with liver cirrhosis. Hepatogastroenterology. 2003;50:814-816.
10. Sidlova K, Pechova M, Akotaska K, Prusa R. Insulin-like growth factor binding protein-3 in patients with liver cirrhosis. Physiol Res. 2002;51:587-590.
11. Thissen JP, Ketelslegers JM, Underwood LE. Nutritional regulation of the insulin-like growth factors. Endocr Rev. 1994;15:80-101.
12. Smith WJ, Underwood LE, Clemmons DR. Effects of caloric or protein restriction on insulin-like growth factor-I and IGF-binding proteins in children and adults. J Clin Endocrinol Metab. 1995;80:443-449.
13. Thissen JP, Pucilowska JB, Underwood LE. Differential regulation of insulin-like growth factor-I (IGF-I) and IGF binding protein-1 messenger ribonucleic acids by amino acid availability and growth hormone in rat hepatocyte primary culture. Endocrinology. 1994;134:1570-1576.
14. Oster MH, Fielder PJ, Levin N, Cronin MJ. Adaptation of the growth hormone and insulin-like growth factor-I axis to chronic and severe calorie or protein malnutrition. J Clin Invest. 1995;95:2258-2265.
15. Mendenhall CL, Moritz TE, Roselle GA, et al. A study of oral nutritional support with oxandrolone in malnourished patients with alcoholic hepatitis: results of a Department of Veterans Affairs Cooperative Study. Hepatology. 1993;17:564-576.
16. Mezey E, Caballeria J, Mitchell MC, Pares A, Herlong HF, Rodes J. Effect of parenteral amino acid supplementation on short-term and long-term outcomes in severe alcoholic hepatitis: a randomized controlled clinical trial. Hepatology. 1991;1:1090-1096.
17. Kearns PJ, Young H, Garcia G, et al. Accelerated improvement of alcoholic liver disease with enteral nutrition. Gastroenterology. 1992;102:200-205.
18. Platell C, Kong SE, McCauley R, Hall JC. Branched-chain amino acids. J Gastroenterol Hepatol. 2000;15:706-717.
19. Neyra NR, Hakim RM, Shyr Y, Ikizler TA. Serum transferrin and serum prealbumin are early predictors of serum albumin in chronic hemodialysis patients. J Ren Nutr. 2000;10:184-190.
20. Scholzen T, Gerdes J. The Ki-67 Protein: from the known and the unknown. J Cell Physiol. 2000;182:311-322.
21. Niu Q, Tang ZY, Ma ZC, Qin LX, Zhang LH. Serum vascular endothelial growth factor is a potential biomarker of metastatic recurrence after curative resection of hepatocellular carcinoma. World J Gastroenterol. 2000;6:565-568.
22. Shimada M, Takenaka K, Gion T, et al. Prognosis of recurrent hepatocellular carcinoma: a 10-year surgical experience in Japan. Gastroenterology. 1996;111:720-726.
23. Rajah R, Valentinis B, Cohen P. Insulin-like growth factor (IGF)-binding protein-3 induces apoptosis and mediates the effects of transforming growth factor-beta 1 on programmed cell death through a p53-and IGF-independent mechanism. J Biol Chem. 1997;272:12181-12188.
24. Lin YW, Kubota M, Wakazono Y, et al. Normal mutation frequencies of somatic cells in patients receiving growth hormone therapy. Mutat Res. 1996;362:97-103.
25. Bartlett DL, Stein TP, Torosian MH. Effect of growth hormone and protein intake on tumour growth and host cachexia. Surgery. 1995;117:260-267.
26. Moses HL, Robinson RA. Growth factors, growth factor receptors and cell cycle control mechanisms in chemically transformed cells. Fed Proc. 1982;41:3008-3011.
27. Inoue T, Saito H, Fukushima R, et al. Growth hormone and insulin-like growth factor enhance host defence in a murine sepsis model. Arch Surg. 1995;130:1115-1122.
28. Tacke J, Bolder U, Herrmann A, Berger G, Jauch KW. Long-term risk of gastrointestinal tumor recurrence after postoperative treatment with recombinant human growth hormone. JPEN J Parenter Enteral Nutr. 2000;24:140-144.
29. Liu W, Jiang Z, Wang X, Shu H, Cui W, Wilmore DW. Impact of perioperative treatment of recombinant human growth hormone on cell immune function and intestinal barrier function: randomized, double-blind, controlled trial. World J Surg. 2003;27:412-415.